Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Universitätsklinik für Innere Medizin
Klinische Abteilung für Onkologie
SCI/PUBMED gelistet | alle Publikationstypen | Gesamt nach Jahr und Erstautor | MUG-Autor*innen |
** = Publikationen gelistet in SCI/SSCI/Pubmed
Originalarbeit (Zeitschrift)
** Aftahy, AK; Barz, M; Lange, N; Baumgart, L; Thunstedt, C; Eller, MA; Wiestler, B; Bernhardt, D; Combs, SE; Jost, PJ; Delbridge, C; Liesche-Starnecker, F; Meyer, B; Gempt, J
The Impact of Postoperative Tumor Burden on Patients With Brain Metastases
FRONT ONCOL. 2022; 12: 869764
Doi: 10.3389/fonc.2022.869764
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083
Doi: 10.1002/cam4.4675
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207
Doi: 10.3389/fimmu.2022.840207
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Bartsch, R; Gampenrieder, SP; Rinnerthaler, G; Petru, E; Egle, D; Petzer, A; Balic, M; Pluschnig, U; Sliwa, T; Singer, C
Updated Austrian treatment algorithm in HER2+metastatic breast cancer
WIEN KLIN WOCHENSCHR. 2022; 134(1-2): 63-72.
Doi: 10.1007/s00508-021-01987-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Baumgart, L; Barz, M; Delbridge, C; Aftahy, AK; Janssen, IK; Jost, PJ; Ryang, YM; Meyer, B; Gempt, J
Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia
CURR ONCOL. 2022; 29(9): 6236-6244.
Doi: 10.3390/curroncol29090490
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Blombery, P; Lew, TE; Dengler, MA; Thompson, ER; Lin, VS; Chen, X; Nguyen, T; Panigrahi, A; Handunnetti, SM; Carney, DA; Westerman, DA; Tam, CS; Adams, JM; Wei, AH; Huang, DCS; Seymour, JF; Roberts, AW; Anderson, MA
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood. 2022; 139(8):1198-1207
Doi: 10.1182/blood.2021012775
Web of Science
PubMed
FullText
FullText_MUG
** Brcic, I; Scheipl, S; Bergovec, M; Leithner, A; Szkandera, J; Sotlar, K; Suda, A; Smolle, MA; Kraus, T; Rosenberg, AE; Liegl-Atzwanger, B; Igrec, J
Implementation of Copy Number Variations-Based Diagnostics in Morphologically Challenging EWSR1/FUS::NFATC2 Neoplasms of the Bone and Soft Tissue.
Int J Mol Sci. 2022; 23(24):
Doi: 10.3390/ijms232416196
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Dieckmann, KP; Pokrivcak, T; Geczi, L; Niehaus, D; Dralle-Filiz, I; Matthies, C; Dienes, T; Zschabitz, S; Paffenholz, P; Gschliesser, T; Pichler, R; Mego, M; Bader, P; Zengerling, F; Heinzelbecker, J; Krausewitz, P; Krege, S; Aurilio, G; Aksoy, C; Hentrich, M; Seidel, C; Torzsok, P; Nestler, T; Majewski, M; Hiester, A; Buchler, T; Vallet, S; Studentova, H; Schonburg, S; Niedersuss-Beke, D; Ring, J; Trenti, E; Heidenreich, A; Wulfing, C; Isbarn, H; Pichlmeier, U; Pichler, M
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
THER ADV MED ONCOL. 2022; 14: 17588359221086813
Doi: 10.1177/17588359221086813
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Englisch, C; Konigsbrugge, O; Nopp, S; Moik, F; Quehenberger, P; Preusser, M; Pabinger, I; Ay, C
Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
INT J MOL SCI. 2022; 23(24): 15770
Doi: 10.3390/ijms232415770
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Englisch, C; Moik, F; Nopp, S; Raderer, M; Pabinger, I; Ay, C
ABO blood group type and risk of venous thromboembolism in patients with cancer
BLOOD ADV. 2022; 6(24): 6274-6281.
Doi: 10.1182/bloodadvances.2021006283
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Fluhrer, H; Hutterer, GC; Golbeck, S; Stidl, M; Niedrist, T; Pichler, R; Mischinger, J; Seles, M; Mannweiler, S; Spiegelberg, J; Bauernhofer, T; Jost, PJ; Ahyai, S; Zigeuner, R; Pichler, M; Barth, DA
Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Ther Adv Med Oncol. 2022; 14: 17588359221134065
Doi: 10.1177/17588359221134065
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
** Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stöger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Breast Care (Basel). 2022; 17(2):137-145
Doi: 10.1159/000516157
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
** Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Sanoyan, DA; Maas, C; Uhlig, J; Fenchel, K; Greil, R; VON, DER, Heyde, E; Agocs, GR; Weide, R; Schwager, M; Reichenbach, F; Modest, DP; Fritsch, R
Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.
Anticancer Res. 2022; 42(10):4773-4785
Doi: 10.21873/anticanres.15982
Web of Science
PubMed
FullText
FullText_MUG
** Gressenberger, P; Posch, F; Pechtold, M; Gütl, K; Muster, V; Jud, P; Riedl, J; Silbernagel, G; Kolesnik, E; Schmid, J; Raggam, RB; Brodmann, M; Gary, T
Lipoprotein(a) and Pulmonary Embolism Severity-A Retrospective Data Analysis.
Front Cardiovasc Med. 2022; 9: 808605
Doi: 10.3389/fcvm.2022.808605
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Heilig, CE; Lassmann, A; Mughal, SS; Mock, A; Pirmann, S; Teleanu, V; Renner, M; Andresen, C; Kohler, BC; Aybey, B; Bauer, S; Siveke, JT; Hamacher, R; Folprecht, G; Richter, S; Schrock, E; Brandts, CH; Ahrens, M; Hohenberger, P; Egerer, G; Kindler, T; Boerries, M; Illert, AL; von Bubnoff, N; Apostolidis, L; Jost, PJ; Westphalen, CB; Weichert, W; Keilholz, U; Klauschen, F; Beck, K; Winter, U; Richter, D; Mohrmann, L; Bitzer, M; Schulze-Osthoff, K; Brors, B; Mechtersheimer, G; Kreutzfeldt, S; Heining, C; Lipka, DB; Stenzinger, A; Schlenk, RF; Horak, P; Glimm, H; Hubschmann, D; Frohling, S
Gene expression-based prediction of pazopanib efficacy in sarcoma
EUR J CANCER. 2022; 172: 107-118.
Doi: 10.1016/j.ejca.2022.05.025
Web of Science
PubMed
FullText
FullText_MUG
** Illini, O; Fabikan, H; Hochmair, MJ; Weinlinger, C; Krenbek, D; Brcic, L; Setinek, U; Terbuch, A; Absenger, G; Konjić, S; Valipour, A
Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study.
J Clin Med. 2022; 11(14):
Doi: 10.3390/jcm11144098
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Jahn, A; Rump, A; Widmann, TJ; Heining, C; Horak, P; Hutter, B; Paramasivam, N; Uhrig, S; Gieldon, L; Drukewitz, S; Kubler, A; Bermudez, M; Hackmann, K; Porrmann, J; Wagner, J; Arlt, M; Franke, M; Fischer, J; Kowalzyk, Z; William, D; Weth, V; Oster, S; Frohlich, M; Hullein, J; Gonzalez, CV; Kreutzfeldt, S; Mock, A; Heilig, CE; Lipka, DB; Mohrmann, L; Hanf, D; Oles, M; Teleanu, V; Allgauer, M; Ruhnke, L; Kutz, O; Knurr, A; Lassmann, A; Endris, V; Neumann, O; Penzel, R; Beck, K; Richter, D; Winter, U; Wolf, S; Pfutze, K; Georg, C; Meissburger, B; Buchhalter, I; Augustin, M; Aulitzky, WE; Hohenberger, P; Kroiss, M; Schirmacher, P; Schlenk, RF; Keilholz, U; Klauschen, F; Folprecht, G; Bauer, S; Siveke, JT; Brandts, CH; Kindler, T; Boerries, M; Illert, AL; von Bubnoff, N; Jost, PJ; Metzeler, KH; Bitzer, M; Schulze-Osthoff, K; von Kalle, C; Brors, B; Stenzinger, A; Weichert, W; Hubschmann, D; Frohling, S; Glimm, H; Schrock, E; Klink, B
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
ANN ONCOL. 2022; 33(11): 1186-1199.
Doi: 10.1016/j.annonc.2022.07.008
Web of Science
PubMed
FullText
FullText_MUG
** Juracek, J; Madrzyk, M; Stanik, M; Ruckova, M; Trachtova, K; Malcikova, H; Lzicarova, E; Barth, DA; Pichler, M; Slaby, O
A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer
PROSTATE. 2022;
Doi: 10.1002/pros.24466
Web of Science
PubMed
FullText
FullText_MUG
** Klec, C; Knutsen, E; Schwarzenbacher, D; Jonas, K; Pasculli, B; Heitzer, E; Rinner, B; Krajina, K; Prinz, F; Gottschalk, B; Ulz, P; Deutsch, A; Prokesch, A; Jahn, SW; Lellahi, SM; Perander, M; Barbano, R; Graier, WF; Parrella, P; Calin, GA; Pichler, M
ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform.
Cell Mol Life Sci. 2022; 79(7): 391
Doi: 10.1007/s00018-022-04402-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Krstic, J; Reinisch, I; Schindlmaier, K; Galhuber, M; Riahi, Z; Berger, N; Kupper, N; Moyschewitz, E; Auer, M; Michenthaler, H; Nössing, C; Depaoli, MR; Ramadani-Muja, J; Usluer, S; Stryeck, S; Pichler, M; Rinner, B; Deutsch, AJA; Reinisch, A; Madl, T; Chiozzi, RZ; Heck, AJR; Huch, M; Malli, R; Prokesch, A
Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism.
Sci Adv. 2022; 8(3):eabh2635
Doi: 10.1126/sciadv.abh2635
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Maisel, F; Smolle, MA; Mollnar, S; Riedl, JM; Barth, DA; Seles, M; Terbuch, A; Rossmann, CH; Eisner, F; Mannweiler, S; Hutterer, G; Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, M; Gerger, A; Jost, PJ; Bauernhofer, T; Pichler, M; Posch, F
Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Clin Genitourin Cancer. 2022; 20(4):344-353
Doi: 10.1016/j.clgc.2022.03.010
Web of Science
PubMed
FullText
FullText_MUG
** Meinhardt, AL; Munkhbaatar, E; Höckendorf, U; Dietzen, M; Dechant, M; Anton, M; Jacob, A; Steiger, K; Weichert, W; Brcic, L; McGranahan, N; Branca, C; Kaufmann, T; Dengler, MA; Jost, PJ
The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
Oncogene. 2022; 41(9):1376-1382
Doi: 10.1038/s41388-021-02161-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Minichsdorfer, C; Fuereder, T; Leutner, M; Singer, CF; Kacerovsky-Strobl, S; Egle, D; Greil, R; Balic, M; Fitzal, F; Pfeiler, G; Frantal, S; Bartsch, R; Gnant, M
Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.
ESMO Open. 2022; 7(2):100426
Doi: 10.1016/j.esmoop.2022.100426
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Mischinger, J; Schöllnast, H; Zurl, H; Geyer, M; Fischereder, K; Adelsmayr, G; Igrec, J; Fritz, G; Merdzo-Hörmann, M; Elstner, J; Schmid, J; Triebl, A; Trimmel, V; Reiter, C; Steiner, J; Rosenlechner, D; Seles, M; Pichler, GP; Pichler, M; Riedl, J; Schöpfer-Schwab, S; Strobl, J; Hutterer, GC; Zigeuner, R; Pummer, K; Augustin, H; Ahyai, S; Mannweiler, S; Fuchsjäger, M; Talakic, E
Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Front Surg. 2022; 9: 1013389
Doi: 10.3389/fsurg.2022.1013389
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Colling, M; Mahé, I; Jara-Palomares, L; Pabinger, I; Ay, C
Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review.
J THROMB HAEMOST. 2022; 20(3): 619-634.
Doi: 10.1111/jth.15599
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Pelzmann, B; Hatab, A; Scheruebel, S; Langthaler, S; Rienmueller, T; Sokolowski, A; Gorischek, A; Platzer, D; Zorn-Pauly, K; Jahn, SW; Bauernhofer, T; Schreibmayer, W
Consequences of somatic mutations of GIRK1 detected in primary malign tumors on expression and function of G-protein activated, inwardly rectifying, K+ channels
FRONT ONCOL. 2022; 12: 998907
Doi: 10.3389/fonc.2022.998907
Web of Science
FullText
FullText_MUG
** Posch, F; Niedrist, T; Glantschnig, T; Firla, S; Moik, F; Kolesnik, E; Wallner, M; Verheyen, N; Jost, PJ; Zirlik, A; Pichler, M; Balic, M; Rainer, PP
Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer.
Front Cardiovasc Med. 2022; 9: 933428
Doi: 10.3389/fcvm.2022.933428
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Pototschnig, I; Feiler, U; Diwoky, C; Vesely, PW; Rauchenwald, T; Paar, M; Bakiri, L; Pajed, L; Hofer, P; Kashofer, K; Sukhbaatar, N; Schoiswohl, G; Weichhart, T; Hoefler, G; Bock, C; Pichler, M; Wagner, EF; Zechner, R; Schweiger, M
Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL/6 model of cancer-associated cachexia
J CACHEXIA SARCOPENI. 2022;
Doi: 10.1002/jcsm.13109
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Pratsinis, M; Fankhauser, C; Pratsinis, K; Beyer, J; Bührer, E; Cathomas, R; Fischer, N; Hermanns, T; Hirschi-Blickenstorfer, A; Kamradt, J; Alex, Kluth, L; Zihler, D; Mingrone, W; Müller, B; Nestler, T; Rothschild, SI; Seifert, B; Templeton, AJ; Terbuch, A; Ufen, MP; Woelky, R; Gillessen, S; Rothermundt, C
Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
Eur Urol Open Sci. 2022; 40: 16-18.
Doi: 10.1016/j.euros.2022.03.013
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Prinz, F; Jonas, K; Balihodzic, A; Klec, C; Reicher, A; Barth, DA; Riedl, J; Gerger, A; Kiesslich, T; Mayr, C; Rinner, B; Kargl, J; Pichler, M
MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.
RNA Biol. 2022; 19(1):1305-1315
Doi: 10.1080/15476286.2022.2152978
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Reissig, TM; Uhrig, S; Jost, PJ; Luchini, C; Vicentini, C; Liffers, ST; Allgauer, M; Adsay, V; Scarpa, A; Lawlor, RT; Frohling, S; Stenzinger, A; Kloppel, G; Schildhaus, HU; Siveke, JT
MCL1 as putative target in pancreatoblastoma
VIRCHOWS ARCH. 2022;
Doi: 10.1007/s00428-022-03349-w
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Remschmidt, B; Gaessler, J; Brcic, L; Wallner, J; Muallah, D; Rieder, M
The impact of COVID-19 on oral squamous cell carcinoma's diagnostic stage-A retrospective study.
Oral Dis. 2022;
Doi: 10.1111/odi.14441
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645
Doi: 10.1055/a-1548-4847
Web of Science
PubMed
FullText
FullText_MUG
** Rinnerthaler, G; Singer, C; Petru, E; Egle, D; Petzer, A; Pluschnig, U; Gampenrieder, SP; Pfeiler, G; Gnant, M; Grunberger, B; Krippl, P; Strasser-Weippl, K; Suppan, C; Brunner, C; Pusch, R; Sandholzer, M; Balic, M; Bartsch, R
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
WIEN KLIN WOCHENSCHR. 2022;
Doi: 10.1007/s00508-022-02082-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Schlintl, V; Huemer, F; Rinnerthaler, G; Melchardt, T; Winder, T; Reimann, P; Riedl, J; Amann, A; Eisterer, W; Romeder, F; Piringer, G; Ilhan-Mutlu, A; Woll, E; Greil, R; Weiss, L
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
BMC CANCER. 2022; 22(1): 51
Doi: 10.1186/s12885-021-09115-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Seidel, MG; Kashofer, K; Moser, T; Thueringer, A; Liegl-Atzwanger, B; Leithner, A; Szkandera, J; Benesch, M; El-Heliebi, A; Heitzer, E
Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents.
Front Pediatr. 2022; 10: 926405
Doi: 10.3389/fped.2022.926405
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Singer, CF; Holst, F; Steurer, S; Burandt, EC; Lax, SF; Jakesz, R; Rudas, M; Stoger, H; Greil, R; Sauter, G; Filipits, M; Simon, R; Gnant, M; Abcsg, ABCSG
Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer
CLIN CANCER RES. 2022; 28(18): 4112-4120.
Doi: 10.1158/1078-0432.CCR-21-4328
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Smolle, MA; Musser, E; Bergovec, M; Friesenbichler, J; Wibmer, CL; Leitner, L; Sørensen, MS; Petersen, MM; Brcic, I; Szkandera, J; Scheipl, S; Leithner, A
Survival Prediction in Patients Treated Surgically for Metastases of the Appendicular Skeleton-An External Validation of 2013-SPRING Model.
Cancers (Basel). 2022; 14(14):
Doi: 10.3390/cancers14143521
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Suppan, C; Graf, R; Jahn, S; Zhou, Q; Klocker, EV; Bartsch, R; Terbuch, A; Kashofer, K; Regitnig, P; Lindenmann, J; Posch, F; Gerritsmann, H; Jost, PJ; Heitzer, E; Dandachi, N; Balic, M
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer. 2022; 126(3):456-463
Doi: 10.1038/s41416-021-01601-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J
Keeping up the 'race pace' in a patient with nonuterine leiomyosarcoma
FUTURE ONCOL. 2022;
Doi: 10.2217/fon-2022-0636
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
** Terbuch, A; Posch, F; Bauernhofer, T; Jost, PJ; Partl, R; Stranzl-Lawatsch, H; Baciarello, G; Fizazi, K; Giannatempo, P; Verzoni, E; Sweeney, C; Ravi, P; Tran, B; Basso, U; White, J; Vincenzi, B; Oing, C; Cutuli, HJ; Dieckmann, KP; Gamulin, M; Chovanec, M; Fankhauser, CD; Heidenreich, A; Mohamad, O; Thibault, C; Fischer, S; Gillessen, S, , International, Germ, Cell, Cancer, Collaborative, Group
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2022; 113(4):825-832
Doi: 10.1016/j.ijrobp.2022.03.021
Web of Science
PubMed
FullText
FullText_MUG
** Uhl, B; Prochazka, KT; Pansy, K; Wenzl, K; Strobl, J; Baumgartner, C; Szmyra, MM; Waha, JE; Wolf, A; Tomazic, PV; Steinbauer, E; Steinwender, M; Friedl, S; Weniger, M; Küppers, R; Pichler, M; Greinix, HT; Stary, G; Ramsay, AG; Apollonio, B; Feichtinger, J; Beham-Schmid, C; Neumeister, P; Deutsch, AJ
Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
Int J Mol Sci. 2022; 23(14):
Doi: 10.3390/ijms23147874
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Westphal, T; Gampenrieder, SP; Rinnerthaler, G; Balic, M; Posch, F; Dandachi, N; Hauser-Kronberger, C; Reitsamer, R; Sotlar, K; Radl, B; Suppan, C; Stöger, H; Greil, R
Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT).
Breast Care (Basel). 2022; 17(1): 1-9.
Doi: 10.1159/000512467
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
** Wirth, AK; Wange, L; Vosberg, S; Henrich, KO; Rausch, C; Özdemir, E; Zeller, CM; Richter, D; Feuchtinger, T; Kaller, M; Hermeking, H; Greif, PA; Senft, D; Jurinovic, V; Bahrami, E; Jayavelu, AK; Westermann, F; Mann, M; Enard, W; Herold, T; Jeremias, I
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Leukemia. 2022; 36(12):2863-2874
Doi: 10.1038/s41375-022-01726-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Clin Cancer Res. 2022; 28(4):697-707
Doi: 10.1158/1078-0432.CCR-21-3231
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Kurzbericht/Letter
** Buchacher, L; Richtig, G; Schöffl, C; Richtig, E; Koch, L
Long-term adherence to melanoma follow-up examinations - a telephone survey.
J Eur Acad Dermatol Venereol. 2022; 36(9):e710-e712
Doi: 10.1111/jdv.18177
Web of Science
PubMed
FullText
FullText_MUG
** Dill, V; Wagner, CV; Keller, EC; Fernandez-Hernandez, FJ; Shoumariyeh, K; Odinius, TO; Buschhorn, L; Hauch, RT; Suren, C; Hecker, JS; Herhaus, P; Sandherr, M; Schmidt, B; Slotta-Huspenina, J; Bassermann, F; Höckendorf, U; Jilg, S; Branca, C; Vosberg, S; Jost, PJ
Elevated RIPK3 correlates with disease burden in myelofibrosis.
Blood Adv. 2022;
Doi: 10.1182/bloodadvances.2021006838
PubMed
FullText
FullText_MUG
** Terbuch, A; Absenger, G
Neoadjuvant treatment in non-small-cell lung cancer-the earlier, the better
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00828-3
Web of Science
FullText
FullText_MUG
Übersichtsarbeit
** Balihodzic, A; Prinz, F; Dengler, MA; Calin, GA; Jost, PJ; Pichler, M
Non-coding RNAs and ferroptosis: potential implications for cancer therapy.
Cell Death Differ. 2022; 29(6):1094-1106
Doi: 10.1038/s41418-022-00998-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Dankner, M; Wang, Y; Fazelzad, R; Johnson, B; Nebhan, CA; Dagogo-Jack, I; Myall, NJ; Richtig, G; Bracht, JWP; Gerlinger, M; Shinozaki, E; Yoshino, T; Kotani, D; Fangusaro, JR; Gautschi, O; Mazieres, J; Sosman, JA; Kopetz, S; Subbiah, V; Davies, MA; Groover, AL; Sullivan, RJ; Flaherty, KT; Johnson, DB; Benedetti, A; Cescon, DW; Spreafico, A; Zogopoulos, G; Rose, AAN
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
JCO Precis Oncol. 2022; 6:e2200107
Doi: 10.1200/PO.22.00107
PubMed
FullText
FullText_MUG
** Hauser, H; Hammer, R; Schollnast, H; Humer-Fuchs, U; Kriegl, D; Fuchsjager, M; Schmidt, F; Balic, M; Lax, SF
Malignant phyllodes tumor of the breast with axillary lymph node metastasis: case report and review of the literature
EUR SURG. 2022;
Doi: 10.1007/s10353-022-00760-0
(- Case Report)
Web of Science
FullText
FullText_MUG
** Hutterer, GC; Pichler, M
Renal cell carcinoma-presentation highlights from the ESMO Congress 2021
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00798-6
Web of Science
FullText
FullText_MUG
** Jahn, SW; Jost, PJ
Challenges in integrating molecular profiles into clinical cancer care
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00838-1
Web of Science
FullText
FullText_MUG
** Khorana, AA; Mackman, N; Falanga, A; Pabinger, I; Noble, S; Ageno, W; Moik, F; Lee, AYY
Cancer-associated venous thromboembolism.
Nat Rev Dis Primers. 2022; 8(1): 11
Doi: 10.1038/s41572-022-00336-y
Web of Science
PubMed
FullText
FullText_MUG
** Klocker, EV; Balic, M; Steger, G
Molecular profiling leading to personalized treatment in breast cancer
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-021-00792-4
Web of Science
FullText
FullText_MUG
** Moik, F; Ay, C
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies
THROMB RES. 2022; 213: S58-S65.
Doi: 10.1016/j.thromres.2022.01.004
Web of Science
FullText
FullText_MUG
** Moik, F; Ay, C
Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer
J THROMB HAEMOST. 2022;
Doi: 10.1111/jth.15880
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Sanfilippo, KM; Moik, F; Candeloro, M; Ay, C; Di Nisio, M; Lee, AYY
Unanswered questions in cancer-associated thrombosis
BRIT J HAEMATOL. 2022;
Doi: 10.1111/bjh.18276
Web of Science
PubMed
FullText
FullText_MUG
** Wahida, A; Buschhorn, L; Frohling, S; Jost, PJ; Schneeweiss, A; Lichter, P; Kurzrock, R
The coming decade in precision oncology: six riddles
NAT REV CANCER. 2022;
Doi: 10.1038/s41568-022-00529-3
Web of Science
PubMed
FullText
FullText_MUG
Editorial
** Bartsch, R; Balic, M
EVOLUTION OF HER2-TARGETING IN METASTATIC BREAST CANCER
BREAST CARE. 2022;
Doi: 10.1159/000528002
Web of Science
FullText
FullText_MUG
** Dandachi, N; Balic, M
Deciphering the molecular landscape of metastatic lobular breast cancer
EBIOMEDICINE. 2022; 86: 104385
Doi: 10.1016/j.ebiom.2022.104385
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Lindner, AK; Pichler, M; Thurnher, M; Pichler, R
Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma.
Eur Urol. 2022; 81(1): 1-2.
Doi: 10.1016/j.eururo.2021.10.025
Web of Science
PubMed
FullText
FullText_MUG
** Pichler, M
Best of ASCO 2022-bladder cancer
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00847-0
Web of Science
FullText
FullText_MUG
** Suppan, C
ESMO 2021-my top three abstracts in breast cancer
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00810-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Fallbericht
** Huemer, M; Jahn-Kuch, D; Hofmann, G; Pichler, M
A case report of immediate effects of acupuncture on neuropathic cancer breakthrough pain.
Complement Ther Clin Pract. 2022; 48: 101599
Doi: 10.1016/j.ctcp.2022.101599
Web of Science
PubMed
FullText
FullText_MUG
Rezension
** Balic, M; Wimmer, K; Suppan, C; Silovski, T; Brunner, C
Expert Discussion: ASCO 2022
BREAST CARE. 2022; 17(4): 430-436.
Doi: 10.1159/000525966
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; McGranahan, N; Jost, P
Inflammatory cell death acts as tumor suppressor in lung adenocarcinoma
INTERNIST. 2022; 63(SUPPL 3):338-339.
[Oral Communication]
Web of Science
** Balic, M; Posch, F; Bartsch, R
Phase II Study of Neratinib and Trastuzumab plus -oral Vinorelbine in previously treated metastatic Her2 positive Breast Cancer
ONCOL RES TREAT. 2022; 45(SUPPL 2): 106-106.
[Poster]
Web of Science
** Bonnin-Gruber, Y; Schroder, J; Forstbauer, H; Kisro, J; Welslau, M; Muller-Huesmann, H; Burkle, D; Krammer-Steiner, B; von der Heyde, E; Reichenbach, F; Arnold, D; Fritsch, R; Gerger, A; Hegewisch-Becker, S; Vogel, A; Winder, T; Koeberle, D; Prager, G; Stintzing, S
Patient characteristics at baseline in the BERING CRC study: real-world data on BRAF V600E-mutated metastatic colorectal cancer
ONCOL RES TREAT. 2022; 45(SUPPL 2): 315-316.
[Poster]
Web of Science
** Brcic, L; Zacharias, M; Konjic, S; Kashofer, K; Absenger, G; Jost, PJ; Wurm, R; Lindenmann, J; Terbuch, A
Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A singlecenter experience
ANN ONCOL. 2022; 38(9): S1557-S1557.
Doi: 10.1016/j.annonc.2022.10.344
[Poster]
Web of Science
FullText
FullText_MUG
** Dutta, S; Kerbs, P; Rothenberg-Thurley, M; Ksienzyk, B; Krebs, S; Blum, H; Spiekermann, K; Metzeler, KH; Herold, T; Vosberg, S; Greif, PA
Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature
BLOOD. 2022; 140: 8912-8913.
Doi: 10.1182/blood-2022-168939
Web of Science
FullText
FullText_MUG
** El-Heliebi, A; Prietl, B; Mahdy-Ali, K; Purkart, TU; Gerlitz, L; Skofler, C; Stanzer, S; Franz, J; Harbusch, N; Madl, T; Widhalm, G; Rossler, K; Tomberger, M; Mattersdorfer, K; Kroneis, T; Oberhuber, M; Pieber, TR
Next generation drug screening platform: generation of patient-derived cells for ex vivo drug response studies of gliomas
NEURO-ONCOLOGY. 2022; 24: -Brain Tumor Meeting 2022; May 19-20, 2022; Berlin, GERMANY.
Doi: 10.1093/neuonc/noac174.180
[Poster]
Web of Science
FullText
FullText_MUG
** Englisch, C; Konigsbrugge, O; Moik, F; Quehenberger, P; Preusser, M; Pabinger, I; Ay, C
Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer
THROMB RES. 2022; 213: S12-S12.-11th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); MAY 27-29, 2022; Bergamo, ITALY.
[Oral Communication]
Web of Science
** Fischer, S; Rothermundt, C; Stalder, O; Terbuch, A; Hermanns, T; Zihler, D; Muller, B; Hirschi-Blickenstorfer, A; Seifert, B; Kluth, LA; Ufe, MP; Mingrone, W; Templeton, A; Fischer, N; Rothschild, S; Beyer, J; Woelky, R; Gillessen, S; Cathomas, R
Importance of tumor markers in the detection of recurrences - Findings from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
ONCOL RES TREAT. 2022; 45(SUPPL 2):209-209.-DGHO 2022;
[Poster]
Web of Science
** Harbeck, N; Wrobel, D; Zaiss, M; Guth, D; Distelrath, A; Terhaag, J; Lorenz, A; Bartsch, R; Breitenstein, U; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Luftner, D
Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ANN ONCOL. 2022; 33: S157-S157.
Doi: 10.1016/j.annonc.2022.03.091
[Poster]
Web of Science
FullText
FullText_MUG
** Heinemann, V; von Weikersthal, LF; Fuchs, M; Kaiser, F; Heinrich, K; Modest, D; Hofheinz, R; Decker, T; Gerger, A; Angermeier, S; Rumpold, H; Dickhut, A; Ohler, L; Grunberger, B; Niedersuss-Beke, D; Sandmann, M; Kasper, S; Prager, G; Stintzing, S
FIRE-4 (AIO-KRK-0114): Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab - secondary endpoint
ANN ONCOL. 2022; 33: S363-S364.
Doi: 10.1016/j.annonc.2022.04.415
[Poster]
Web of Science
FullText
FullText_MUG
** Hochmair, M; Absenger, G; Ay, L; Robinson, I; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipou, A
Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients
J THORAC ONCOL. 2022; 17(9): S561-S561.
[Poster]
Web of Science
** Hochmair, M; Schmidinger, M; Ay, L; Robinson, I; Absenger, G; Pichler, M; Nguyen, VA; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A
BiomeOne: multi-center Validation of a new microbiome-based Biomarker to predict Response to Cancer Immunotherapy
ONCOL RES TREAT. 2022; 45(SUPPL 2):229-229.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
** Illini, O; Fabikan, H; Hochmair, MJ; Weinlinger, C; Krenbek, D; Brcic, L; Setinek, U; Terbuch, A; Absenger, G; Konji, S; Valipour, A
Characteristics and treatment outcomes in advanced stage non-small cell lung cancer patients with KRAS G12C mutation
WIEN KLIN WOCHENSCHR. 2022; 134(19-20):727-728.
Web of Science
** Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J
Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
LAB INVEST. 2022; 102(SUPPL 1): 613-613.
[Poster]
Web of Science
** Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J
Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
MODERN PATHOL. 2022; 35(SUPPL 2): 613-613.
[Poster]
Web of Science
** Lembeck, A; Zebisch, A; Quehenberger, F; Wolfler, A
Pravalenz von Pilz- und Fisch-formigen Erythrozyten in verschiedenen hamatologischen Erkrankungen
ONCOL RES TREAT. 2022; 45(SUPPL 2):290-291.
[Poster]
Web of Science
** Luftner, D; Bartsch, R; Breitenstein, U; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Schwitter, M; Zaman, K; Wrobel, D; Guth, D; Terhaag, J; Zaiss, M; Distelrath, A; Lorenz, A; Schinkothe, T; Harbeck, N
Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ONCOL RES TREAT. 2022; 45(SUPPL 3): 20-21.
[Poster]
Web of Science
** Marme, F; Hanusch, C; Furlanetto, J; Morris, P; Link, T; Denkert, C; Fasching, PA; Jackisch, C; Antolin, S; Solbach, C; Aftimos, P; Huober, J; Untch, M; Balic, M; Reinisch, M; Blohmer, JU; Concalves, A; Rey, J; Buchele, T; Loibl, S
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT)
ONCOL RES TREAT. 2022; 45(SUPPL 3): 30-30.
[Poster]
Web of Science
** Marme, F; Hanusch, C; Furlanetto, J; Morris, P; Link, T; Denkert, C; Fasching, PA; Jackisch, C; Antolin, S; Solbach, C; Aftimos, P; Huober, J; Untch, M; Balic, M; Reinisch, M; Blohmer, JU; Goncalves, A; Rey, J; Buchele, T; Loibl, S
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
ANN ONCOL. 2022; 33: S148-S149.
Doi: 10.1016/j.annonc.2022.03.074
[Poster]
Web of Science
FullText
FullText_MUG
** Moik, F; Kraler, S; Montecucco, F; Liberale, L; Nopp, S; Englisch, C; Lapikova-Bryhinska, T; Akhmedov, A; von Eckardstein, A; Wenzl, FA; Pabinger, I; Luscher, TF; Ay, C
Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer
BLOOD. 2022; 140: 1255-1256.
Doi: 10.1182/blood-2022-163287
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251.
Doi: 10.1182/blood-2022-160087
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Pfeiler, G; Hlauschek, D; Mayer, EL; Deutschmann, C; Kacerovsky-Strobl, S; Martin, M; Meisel, JL; Zdenkowski, N; Loibl, S; Balic, M; Park, H; Prat, A; Isaacs, C; Machacek-Link, J; Schurmans, C; Theall, KP; Fesl, C; Dueck, AC; DeMichele, A; Gnant, M
Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
J CLIN ONCOL. 2022; 40(16):
[Poster]
Web of Science
** Prager, G; Hubner, G; Schroder, J; Forstbauer, H; Kisro, J; Welslau, M; Burkle, D; Von der Heyde, E; Muller-Huesmann, H; Krammer-Steiner, B; Hering-Schubert, C; Popper, U; Gerger, A; Greil, R; Reichenbach, F; Arnold, D; Fritsch, R; Hegewisch-Becker, S; Vogel, A; Wagner, AD; Winder, T; Koeberle, D; Stintzing, S
Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, non-interventional study in Germany, Austria and Switzerland - BERING CRC
ONCOL RES TREAT. 2022; 45(SUPPL 3): 64-64.
[Poster]
Web of Science
** Prietl, B; Odler, B; Kirsch, AH; Artinger, K; Eigner, M; Schmaldienst, S; Pfeifer, V; Stanzer, S; Eberl, A; Raml, R; Rosenkranz, A; Brodmann, M; Eller, P; Pieber, T; Eller, K
CHRONIC INFLAMMATION MIGHT PROTECT HAEMODIALYSIS PATIENTS FROM SEVERE COVID-19
NEPHROL DIAL TRANSPL. 2022; 37: I106-I106.
[Poster]
Web of Science
** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
** Robinson, I; Hochmair, MJ; Jansen, C; Pacifico, C; Sladek, B; Knabl, A; Gasche, N; Absenger, G; Pichler, M; Valipour, A
Prediction of immune checkpoint inhibitor (ICI) response in non-small cell lung cancer (NSCLC) patients using a microbiome-based biomarker
WIEN KLIN WOCHENSCHR. 2022; 134(19-20): 742-742.
[Poster]
Web of Science
** Robinson, I; Schmidinger, M; Hochmair, MJ; Ay, L; Absenger, G; Pichler, M; Nguyen, VAF; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A
BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy
ANN ONCOL. 2022; 33(7):S592-S592.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); SEP 09-13, 2022; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2022.07.149
[Poster]
Web of Science
FullText
FullText_MUG
** Ruhnke, L; Frimmel, J; Rollig, C; Mohr, B; Altmann, H; Poitz, D; Zukunft, S; Schranz, K; Vosberg, S; Spiekermann, K; von Bergwelt, M; Jost, E; Dressler, S; Schafer-Eckart, K; Chavakis, T; Aust, D; Johrens, K; Baretton, G; Bornhauser, M; Greif, PA; Stolzel, F; Herold, S; Wagenfuhr, L
Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia
BLOOD. 2022; 140: 3454-3455.
Doi: 10.1182/blood-2022-166271
Web of Science
FullText
FullText_MUG
** Schranz, A; Sternad, C; Mischinger, HJ; Wagner, D; Jost, PJ; Riedl, J; Wolfler, A; Pieber, T; Sourij, H; Aberer, F
Incidence of diabetes and its impact on survival after pancreatic tumor surgery - a retrospective data analysis
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 4):258-259.-Jahrestagung der Österreichischen Diabetesgesellschaft ;
[Poster]
Web of Science
** Singer, CF; Egle, D; Greil, R; Petru, E; Ohler, L; Balic, M; Tinchon, C; Pfeiler, G; Marhold, M; Brunner, C; Haider, K; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Uthman, S; Mraz, B; Bartsch, R
REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis
ANN ONCOL. 2022; 33: S217-S217.
Doi: 10.1016/j.annonc.2022.03.214
[Poster]
Web of Science
FullText
FullText_MUG
** Stintzing, S; Hubner, G; Schroder, J; Forstbauer, H; Kisro, J; Welslau, M; Muller-Huesmann, H; Burkle, D; Krammer-Steiner, B; von der Heyde, E; Reichenbach, F; Arnold, D; Fritsch, RM; Gerger, A; Hegewisch-Becker, S; Vogel, A; Wagner, AD; Winder, T; Koeberle, D; Prager, G
Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer.
J CLIN ONCOL. 2022; 40(16): E15584-E15584.
[Poster]
Web of Science
** Stintzing, S; Von Weikersthal, L; Fuchs, M; Kaiser, F; Heinrich, K; Modest, DP; Hofheinz, R; Decker, T; Gerger, A; Angermeier, S; Rumpold, H; Dickhut, A; Ohler, L; Gruenberger, B; Niedersuess-Beke, D; Sandmann, M; Winder, T; Kasper, S; Prager, G; Heinemann, V
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
J CLIN ONCOL. 2022; 40(16):
[Poster]
Web of Science
** Szmyra, MM; Haingartner, S; Jantscher, S; Pansy, K; Uhl, B; Greinix, HT; Neumeister, P; Bernhart, E; Beham-Schmid, C; Dengler, MA; Klosch, B; Deutsch, AJA
The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax
BLOOD. 2022; 140: 4945-4946.
Doi: 10.1182/blood-2022-166678
[Poster]
Web of Science
FullText
FullText_MUG
** Terbuch, A; Walser, G; Stotz, M; Gerger, A; Posch, F; Bauernhofer, T
Thromboprophylaxis and its influence on the risk of thromboembolism in patients with germ cell tumors receiving cisplatin-containing chemotherapy
ONCOL RES TREAT. 2022; 45(SUPPL 2):322-322.
[Poster]
Web of Science
** Troelsen, FS; Vago, EK; Horvath-Puho, E; van Es, N; Mulder, FI; Moik, F; Erichsen, R; Ay, C; Sorensen, HT
KRAS mutation in colorectal cancer and risk of venous thromboembolism: a Danish population-based cohort study
THROMB RES. 2022; 213: S11-S11.-11th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); MAY 27-29, 2022; Bergamo, ITALY.
[Oral Communication]
Web of Science
** Villalona-Calero, MA; Patnaik, A; Maki, RG; O'Neil, B; Abbruzzese, JL; Dagogo-Jack, I; Devarakonda, S; Wahlroos, S; Lin, CC; Fujiwara, Y; Terbuch, A; Postel-Vinay, S; Goebeler, ME; Addeo, A; Prenen, H; Arkenau, T; Sacher, AG; Liu, CX; Kormany, W; Ahnert, JR
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors
J CLIN ONCOL. 2022; 40(16):
[Poster]
Web of Science
** von der Heyde, E; Burkle, D; Forstbauer, H; Hubner, G; Schmidt, B; Schroder, J; Distelrath, A; Wierecky, J; Stubs, P; Kisro, J; Welslau, M; Muller-Huesmann, H; Gohler, T; Krammer-Steiner, B; Schwaner, I; Hering-Schubert, C; Gerger, A; Greil, R; Jacobasch, L; Reichenbach, F; Stintzing, S; Prager, G
Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC
ANN ONCOL. 2022; 33: S248-S248.
Doi: 10.1016/j.annonc.2022.04.099
[Poster]
Web of Science
FullText
FullText_MUG
** Wagner, N; Lenders, MM; Kuhl, K; Reinhardt, L; Fuchss, M; Ring, N; Richtig, G; Ebel, C; Andre, F; Stager, R; Zellweger, C; Sturmer, SH; Lang, R; Paar, M; Gussek, P; Kimeswenger, S; Oellinger, A; Amaral, T; Forschner, A; Leiter-Stoppke, U; Weide, B; Gassenmaier, M; Schraag, A; Klumpp, B; Hoetzenecker, W; Ziemer, M; Berking, C; Mangana, J; Nguyen, VA; Terheyden, P; Richtig, E; Loquai, C; Diem, S; Cozzio, A; Rocken, M; Garbe, C; Gebhardt, C; Meier, F; Eigentler, T; Flatz, L
Site-specific tumor response and survival in patients with metastatic melanoma receiving immune checkpoint inhibition or targeted therapy: implications for treatment choice
J DTSCH DERMATOL GES. 2022; 20: 3-4.-32. Deutschen Hautkrebskongresses (ADO‐Jahrestagung), 14.–17. September 2022; Sep 14-17, 2022; Hannover, Deutschland.
[Poster]
Web of Science
** Zacharias, M; Konjic, S; Absenger, G; Hochmair, MJ; Fabikan, H; Weinlinger, C; Illini, O; Jost, PJ; Schlintl, V; Wurm, R; Lindenmann, J; Fediuk, M; Brcic, L; Terbuch, A
Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
J THORAC ONCOL. 2022; 17(9): S201-S202.
[Poster]
Web of Science
** Zgubic, JA; Zacharias, M; Wurm, R; Terbuch, A; Brcic, L
Predictive and prognostic relevance of PD-L1 and TIGIT expression in patients with non-small cell lung carcinoma treated with immunotherapy
HISTOPATHOLOGY. 2022; 81: 170-170.
[Poster]
Web of Science